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Objective To compare common extended-spectrum b-lactamase (ESBL) screening meth-
ods and b-lactams for their ability to detect TEM- and SHV-related ESBL enzymes.
Methods This study compared disk diffusion testing by NCCLS methodology, the Jarlier
double disk test, a disk-on-disk test, a modified three-dimensional test and the E test
method for their sensitivity and specificity in detecting TEM- and SHV-related ESBL
producers. Three negative and 22 positive controls were studied. These were two
Klebsiella pneumoniae and 23 Escherichia coli transconjugants. Seventeen b-lactam anti-
biotics were tested: cefamandole, cefotetan, cefoxitin, cefuroxime, cefixime, cefopera-
zone, cefotaxime, cefpodoxime, cefsulodin, ceftazidime, ceftibuten, ceftizoxime,
ceftriaxone, moxalactam, cefepime, cefpirome and aztreonam.
Results NCCLS disk diffusion was 14% sensitive with ceftriaxone, 36% with cefotaxime,
64% with aztreonam, 68% with cefpodoxime, and 73% with ceftazidime. Cefoperazone,
cefamandole, cefpodoxime and cefpirome showed 91% sensitivity using the Jarlier test.
Using the disk-on-disk test, cefsulodin showed 95% sensitivity, and cefoperazone,
cefepime and cefamandole showed 91% sensitivity. With the modified three-dimensional
test, cefoperazone, cefpodoxime and cefpirome showed 91% sensitivity.
Conclusions For practical reasons, we would recommend use of either the Jarlier test or
the commercial cephalosporin disks containing clavulanic acid to screen for ESBL
producers. Cefoperazone, cefamandole, cefpodoxime and cefpirome showed good sen-
sitivity across the methods tested.
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I N T R O D U C T I O N
Extended-spectrum b-lactamase (ESBL) enzymes
pose a real threat to the use of extended-spectrum
b-lactams for treating serious Gram-negative
infections. Generally, they confer resistance to
most b-lactams, with the exception of the cepha-
mycins (cefoxitin and cefotetan) and carbapenems,
while generally retaining susceptibility to the b-
lactamase inhibitors such as clavulanic acid [1].
Although other classes of ESBL exist, the vast
majority are derived from TEM or SHV enzymes,
and the present study therefore focuses on these
enzymes [1]. A key problem in the detection of
ESBL producers is the possibility of low-level
expression of the enzyme and of an inoculum
effect, resulting in variable MIC values and zone
diameters by disk diffusion testing. Consequently,
isolates may be reported by the laboratory as
sensitive to third-generation cephalosporins,
whereas treatment failure may occur with this
group of antibiotics in the in vivo situation [2].
As more traditional isolation and susceptibility
testing methods often fail to detect these organ-
isms, routine diagnostic methods require revision
and standards must be recommended. To date,
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national guidelines for testing and reporting of
ESBL producers have not been developed in the
UK. In the USA, the National Committee for Clin-
ical Laboratory Standards (NCCLS) [3] states that
strains of ESBL-producing Klebsiella species and
Escherichia coli should be screened for with a range
of b-lactams using specific screening breakpoints,
and then confirmed by methods based on differ-
ential zone sizes using both cefotaxime and cefta-
zidime alone and in the presence of clavulanic
acid.
A proportion of UK laboratories use automated
sensitivity-testing systems, although the majority
still use disk diffusion-based methods. Few, how-
ever, routinely measure zone sizes. Several disk
diffusion-based methods have been developed to
screen for ESBL producers; some are easier to
incorporate into routine testing than others. The
aim of this study was to compare five diffusion-
based tests for detecting TEM- and SHV-derived
ESBL producers, four of which are based on the
fact that ESBLs are generally susceptible to clavu-
lanic acid.
M A T E R I A L S A N D M E T H O D S
Bacterial strains
The test strains were all transconjugants, and pro-
duced a sample range of TEM and SHV ESBL
enzymes. Twenty-three of the isolates were E. coli
and two were K. pneumoniae (one TEM-10 and one
TEM-26). They were sent from the laboratories
acknowledged, all of which had previously char-
acterized the b-lactamase enzymes produced by
the strains. Three negative controls producing the
b-lactamase enzymes SHV-1, TEM-1 and TEM-2
were used. The latter two were obtained from the
National Collection of Type Cultures and were
isolates NCTC 50001 and NCTC 50463. Twenty-
two positive controls (producing SHV-2, -3, -4, -5, -
7, and TEM-3, -5, -6, -7, -8, -9, -10, -10, -12, -12, -16, -
17, -24, -26, -26, -28 and -101) were tested. TEM-10
and TEM-12 were received from two different
sources, and all were included in the study. Each
of the isolates is hereafter referred to by the name
of the b-lactamase enzyme it produces.
E. coli ATCC 25922 was used as a control.
Antimicrobial agents
Seventeen commercially available antibiotic disks
were tested (Oxoid, Basingstoke, UK). They
included the second-generation cephalosporins
cefamandole, cefotetan, cefoxitin and cefuroxime,
the third-generation cephalosporins cefixime, cefo-
perazone, cefotaxime, cefpodoxime, cefsulodin,
ceftazidime, ceftibuten, ceftizoxime, ceftriaxone
and moxalactam, the fourth-generation cephalos-
porins cefepime and cefpirome, and the monobac-
tam aztreonam. Cefixime was tested at a potency
of 5 mg/disk, and the others were tested at a
potency of 30 mg/disk. As clavulanic acid disks
are not available in the UK, co-amoxiclav disks
were used as a source of the b-lactamase inhibitor
clavulanic acid, and each contained 20 mg of amox-
icillin and 10 mg of clavulanic acid (Oxoid).
ESBL E test strips (AB Biodisk, Solna, Sweden)
carrying two antibiotic gradients—ceftazidime,
and ceftazidime with clavulanic acid—were used.
M E T H O D S
Disk diffusion testing was carried out according to
NCCLS methodology [3], as it is the most globally
used method. The bacterial inocula were prepared
to a density equivalent to a 0.5 McFarland stan-
dard. Zone sizes were interpreted according to
standard NCCLS breakpoint values for all test
antibiotics and according to NCCLS ESBL screen-
ing breakpoints for cefpodoxime, ceftazidime,
aztreonam, cefotaxime and ceftriaxone. E. coli
ATCC 25922 was included as a control, and all
zone sizes fell within the NCCLS control limits.
The Jarlier double disk test [4] was carried out
by swabbing approximately 5 105 CFU/mL of
each test culture on IsoSensitest (IST) agar. IST
agar is the most commonly used medium for
sensitivity testing in the UK. For each test isolate,
each test b-lactam antibiotic disk was placed
25 mm away from a co-amoxiclav disk. After 18–
24 h of incubation at 37 8C, zones of inhibition
indicating synergy between clavulanic acid and
the b-lactam were looked for. In some cases, it was
necessary to repeat the exercise, placing the disks
either <25 mm or >25 mm apart, in order that the
zones of inhibition met and any interactions
between the antibiotics could be seen.
For the disk-on-disk test, an inoculum of
approximately 5 105 CFU/mL was swabbed on
IST agar. Each of the test antibiotic disks was tested
against each test organism individually and also in
combination with a co-amoxiclav disk. In the latter
case, the co-amoxiclav disk was placed on top of
the cephalosporin disk. The resulting zones of
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inhibition were compared. A test was called posi-
tive if the difference in zone diameters between the
b-lactam disk on its own and in combination with
co-amoxiclav was 5 mm.
The modified three-dimensional test was car-
ried out according to the method described by
Vercauteren et al. [5], with five of the test anti-
biotics: cefoperazone, cefotaxime, cefamandole,
cefpodoxime and ceftazidime. For each test organ-
ism, an inoculum yielding confluent growth after
incubation was swabbed on IST agar. A test anti-
biotic disk was then placed in the middle of the
plate, and a 4-mm well cut out of the agar with a
cork borer, 2 mm away from the antibiotic disk.
The well was then filled with the overnight broth
suspension of the same test organism and the plate
was incubated at 37 8C for 18–24 h. A test was
called positive when the zone of inhibition caused
by the b-lactam disk was reduced or absent around
the well.
ESBL E test strips (AB Biodisk) carry two anti-
biotic gradients—ceftazidime, and ceftazidime
with clavulanic acid—and come with interpreta-
tive guidelines which state that an MIC ratio cef-
tazidime/ceftazidime with clavulanic acid >8 is
indicative of ESBL production. The E test method
was carried out according to the manufacturer’s
instructions. Colonies from an 18–24-h culture
were emulsified in sterile, normal saline to achieve
an inoculum turbidity, equivalent to a 0.5 McFar-
land standard. This inoculum was swabbed on
agar and allowed to dry for 10–15 min. An ESBL
E test strip was then applied to each plate with
sterile forceps and the plate was incubated at 37 8C
for 18 h. After incubation, the MICs were read
according to the manufacturer’s guidelines.
The sensitivity and specificity for each test
were calculated. Sensitivity is a measure of the
success of a test in detecting true positives, and
specificity is a measure of the success of a test in
excluding negatives. Screening tests should ideally
have a sensitivity as close to 100% as possible, with
good specificity. For screening tests, a lack of
sensitivity would be seen as a major drawback,
whereas a lack of specificity would be seen as a
minor drawback.
R E S U L T S
Disk diffusion testing
Standard disk diffusion testing was carried out,
and the zone sizes for each of the test organisms, in
combination with each of the test antibiotics, were
measured and interpreted in light of NCCLS
guidelines. (The cefuroxime results were inter-
preted according to both oral and parenteral
breakpoints.) The number of positive controls
expressing resistance to the test antibiotics is
shown in Figure 1. In addition to the use of stan-
dard NCCLS breakpoints, specific NCCLS ESBL
screening recommendations were followed. This
involved interpreting zone sizes of cefpodoxime,
ceftazidime, aztreonam, cefotaxime and ceftriax-
one in light of specific ESBL breakpoints (Table 2A
in the M2-A7 NCCLS guidelines). Each of the five
antibiotics showed 100% specificity to the isolates
tested. Ceftazidime gave 73% sensitivity, ceftriax-
one 14%, cefotaxime 36%, aztreonam 64%, and
cefpodoxime 68%.
Jarlier double disk test
The Jarlier double disk test gave good sensitivity
and specificity with several b-lactam disks in com-
bination with co-amoxiclav (Figure 2). Notably,
cefoperazone, cefamandole, cefpodoxime and cef-
pirome all exhibited 91% sensitivity. Of the four,
however, only cefpirome showed 100% specificity.
Cefpirome failed to detect only two positive con-
trols, namely TEM-7 and one of the TEM-6 isolates.
The distance between the disks would appear to
be critical for some combinations of antibiotic and
Figure 1 Standard NCCLS disk diffusion testing: % ESBL
producers (n¼ 22) which were categorized as resistant to
specified antibiotics by standard NCCLS breakpoints.
FAM, cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM,
cefuroxime; CFM, cefixime; CFP, cefoperazone; CTX,
cefotaxime; CPD, cefpodoxime; SUL, cefsulodin; CAZ,
ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO,
ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpir-
ome; ATM, aztreonam.
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organism. The Jarlier test was performed 425 times
(25 test isolates 17 antibiotics in combination
with co-amoxiclav). On 57 occasions, the Jarlier
test was negative when the test disks were placed
25 mm away from the co-amoxiclav disk and
became positive when the distance between test
disks was optimized. This optimal distance was
always <25 mm and ranged from 4 to 24 mm.
Placing the disks the standard 25 mm apart would
therefore have resulted in 17% of the isolates
having been reported as false negatives. Table 1
details the number of Jarlier test positives at 25 mm
and <25 mm, and also details the range of opti-
mum distances<25 mm. Results which were nega-
tive at 25 mm, but positive at<25 mm, were due to
the fact that the individual zone sizes were too
small to meet when the disks were 25 mm apart.
When this happened, the radius of each zone was
measured, the radii were combined, and the disks
were subsequently placed this distance apart.
Disk-on-disk test
The reading error of a disk diffusion test is 2 mm
[6]. In comparing two zones of inhibition, the
combined error must be considered, so differences
>4 mm between two zones are considered signifi-
cant. This was the criterion used to establish
whether an isolate was ESBL positive or negative
by the disk-on-disk test. Cefsulodin performed
Figure 2 Jarlier test method: % sensitivity and specificity of
Jarlier test detailed for each antibiotic tested (three ESBL
negative, and 22 ESBL positive). FAM, cefamandole; CTT,
cefotetan; FOX, cefoxitin; CXM, cefuroxime; CFM, cefix-
ime; CFP, cefoperazone; CTX, cefotaxime; CPD, cefpodox-
ime; SUL, cefsulodin; CAZ, ceftazidime; CTB, ceftibuten;
ZOX, ceftizoxime; CRO, ceftriaxone; MOX, moxalactam;
FEP, cefepime; PIR, cefpirome; ATM, aztreonam.
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best with this method, as it was 95% sensitive and
88% specific (Figure 3).
Modified three-dimensional test
The Modified three-dimensional method was per-
formed with a representative seven of the test
antibiotics, chosen because they showed good
sensitivity and specificity by the other methods
tested. Cefoperazone, cefpodoxime and cefpirome
were all 91% sensitive, although cefoperazone was
the only antibiotic to achieve 100% specificity
(Figure 4).
E test method
For the majority of the test isolates, the MIC values
were neither easy nor straightforward to read and
had to be interpreted in light of the interpretation
guidelines issued with the E test strips. Notably, a
large number of isolates exhibited the effect
demonstrated in Figure 5a. In this case, b-lacta-
mase inhibitors at constant levels have extended
the ellipse below the MIC due to intrinsic activity,
and the upper curvature should be extrapolated
towards the strip to get the MIC. Figure 5b also
shows a common effect seen among the test iso-
lates. The E test guidelines state that this is a
phantom inhibition zone. In this case, the ceftazi-
dime MIC is >32 mg/L. The E test guidelines state
that even if the ratio ceftazidime/ceftazidime with
clavulanic acid is less than 8, the isolate should be
reported as ESBL positive if the phantom effect is
present. In this study the ESBL E test strip was
100% specific and 77% sensitive. It failed to detect
SHV-3, TEM-7, one TEM-10, both TEM-12 and the
TEM-17.
Summary
The overall abilities of the different methods to
detect specific ESBL producers (expressed as per-
centage antibiotics detecting ESBL activity by each
method) are detailed in Table 2. It is notable that
the different methods did not differ greatly in their
abilities to detect either SHV or TEM ESBL pro-
ducers with the range of test antibiotics. This study
did show, however, that the methods employed
detected SHV ESBL producers slightly better than
TEM ESBL producers.
D I S C U S S I O N
Although ESBL producers are resistant to cepha-
losporins and penicillins in general (with the
exception of the cephamycins and carbapenems),
many do not appear to be resistant by routine
susceptibility testing. Regardless of their suscept-
ibility pattern in vitro, these isolates should be
reported to the clinician as resistant to relevant
Figure 3 Disk-on-disk test: % sensitivity and specificity of
the disk-on-disk test detailed for each antibiotic tested
(three ESBL positive, and 22 ESBL negative). FAM,
cefamandole; CTT, cefotetan; FOX, cefoxitin; CXM, cefur-
oxime; CFM, cefixime; CFP, cefoperazone; CTX, cefotax-
ime; CPD, cefpodoxime; SUL, cefsulodin; CAZ,
ceftazidime; CTB, ceftibuten; ZOX, ceftizoxime; CRO,
ceftriaxone; MOX, moxalactam; FEP, cefepime; PIR, cefpir-
ome; ATM, aztreonam.
Figure 4 Modified three-dimensional testing: % sensitivity
and specificity of the modified three-dimensional test
detailed for each antibiotic tested (three ESBL negative,
and 22 ESBL positive). FAM, cefamandole; CTT, cefotetan;
FOX, cefoxitin; CXM, cefuroxime; CFM, cefixime; CFP,
cefoperazone; CTX, cefotaxime; CPD, cefpodoxime; SUL,
cefsulodin; CAZ, ceftazidime; CTB, ceftibuten; ZOX,
ceftizoxime; CRO, ceftriaxone; MOX, moxalactam; FEP,
cefepime; PIR, cefpirome; ATM, aztreonam.
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b-lactams. Figure 1 shows the poor performance of
routine disk susceptibility testing detecting b-lac-
tam resistance in ESBL-positive isolates. In a clin-
ical situation, ESBL producers should be reported
as being resistant to all of the antibiotics listed in
Figure 1, with the exception of cefotetan and
cefoxitin. Figure 1 clearly shows that disk diffusion
testing on its own is not capable of detecting low-
level, but highly significant, resistance, and that
routine testing should be backed up by methods
specifically aimed at detecting ESBL activity.
Many methods have been used to identify both
specific ESBL enzymes and ESBL-producing bac-
teria in general [7]. Methods that can be used to
identify specific ESBL enzymes are valuable for
epidemiologic purposes, although they are often
time-consuming and expensive to carry out. They
are generally biochemical or molecular based, and
include isoelectric focusing, single-strand confor-
mational polymorphism and PCR and DNA
sequencing. With increasing incidences of ESBL
producers, it is important that screening to detect
them is incorporated into routine diagnostic test-
ing. Several screening tests have been developed,
but few national sensitivity guidelines have
recommended the use of any one particular
method routinely. In this study, five methods were
evaluated in combination with 17 b-lactam anti-
biotics and 22 SHV- and TEM-related ESBL pro-
ducers. Of primary importance in evaluating a
selection of methods is the determination of their
specificity and sensitivity. Apart from their per-
formances in distinguishing ESBL producers from
non-ESBL producers, the methods tested were
found to be suitable to varying degrees for incor-
poration into routine diagnostic testing.
Where disk diffusion is the routine method of
susceptibility testing, ESBL producers can be
screened for using NCCLS screening criteria. This
method obviously requires no extra resources to
carry out if appropriate antibiotic disks are routi-
nely used. The only necessity is that the zone sizes
are accurately measured, and this may not always
be the case. The current study found that ceftazi-
dime was the best indicator of ESBL activity,
followed by cefpodoxime, using NCCLS guide-
lines. Other investigators, including Emery and
Weymouth [8], have found cefpodoxime to be
superior by this method. The NCCLS does sug-
gest, however, that confirmatory tests be used to
verify the screening results. Reduced MICs for
certain cephalosporins, within the sensitive or
intermediate range, may represent a valid method
of identifying ESBL producers; however, MICs are
not often determined routinely unless some of the
newer automated systems are used, such as the
Vitek [9] or the MicroScan [10]. If disk diffusion is
highly controlled, the zones of inhibition can be
measured and converted to MIC values, although
this is easiest if an automatic zone reader is used.
For laboratories that perform susceptibility test-
ing by disk diffusion, the Jarlier test is easiest to
incorporate into an already existing system. It has
the added benefit that there is no need to measure
zone sizes and the test is easily read by recording
Figure 5 (a) E test—intrinsic activity/extrapolation of
curve to read MIC. (b) E test—paradoxical effect.
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the presence or lack of synergy. The simple
requirement is that a disk containing a b-lactamase
inhibitor, usually clavulanic acid, be placed next to
an appropriate cephalosporin disk. It involves no
additional costs if the disks were to be used any-
way, and requires no extra time in setting up the
test and in reading it. The synergy patterns are
easy to distinguish from regular circular zones of
inhibition, but the operator does need to know
what he is looking for and how to interpret the
patterns. This involves only a minimal amount of
tuition. It has been said of the Jarlier test that the
distance between the co-amoxiclav disk and the
relevant cephalosporin disk is critical. We have
found that some flexibility can be afforded with
respect to the distance, and synergy can be
detected over a range of distances. The synergy
pattern changes slightly as the distance is altered,
but synergy can usually still be detected. Some-
what worrying was the number of positive con-
trols in the present study that tested negative at
25 mm, but positive at reduced distances, down to
4 mm (Table 1). In the Diagnostic Medical Micro-
biology department at Aberdeen Royal Infirmary,
six or eight disks are placed on a 90-mm agar plate
using an Oxoid disk dispenser. Using this system,
the disks are placed either 14 or 21 mm apart, and
this appears to be successful in detecting the local
ESBL producer [11–13]. Occasionally, however, if
an isolate is suspicious and the zones of inhibition
around the co-amoxiclav and cefotaxime disks do
not meet, the test is repeated, varying the distance
between the disks as described in the methods
section. It has been suggested that the Jarlier dou-
ble disk test is not specific to ESBL producers.
Certain species of Enterobacteriaceae hyperpro-
duce chromosomal b-lactamases, which hydrolyze
third-generation cephalosporins and aztreonam
and which are inhibited by clavulanic acid [14].
Although they are not ESBL producers, it would
still be correct to report these isolates as resistant to
the third-generation cephalosporins. This is there-
fore a minor error. For epidemiologic purposes,
further characterization of such isolates would be
necessary, as the Jarlier test alone cannot identify
specific b-lactamase enzymes. Similar to the
Table 2 Percentage of antibiotics detecting ESBL activity by each of five methods tested
% antibiotics detecting ESBL activity by each method
Strain
NCCLS
screening
test n¼ 5
Jarlier
n¼ 17
Disk on disk
n¼ 17
Modified
three-dimensional
n¼ 7
E test
n¼ 1
Sum of
percentages
SHV-2 40 65 59 86 100 350
SHV-3 40 71 65 86 0 262
SHV-4 60 76 71 86 100 393
SHV-5 40 65 47 43 100 295
SHV-7 60 77 82 100 100 419
TEM-3 60 65 59 100 100 384
TEM-5 60 71 76 86 100 393
TEM-6 60 65 65 100 100 390
TEM-7 0 24 24 57 0 105
TEM-8 80 71 65 86 100 402
TEM-9 60 71 71 100 100 402
TEM-10 (Ed) 60 65 71 86 100 382
TEM-10 (NY) 40 35 35 57 100 267
TEM-12 (Ed) 0 35 18 57 0 110
TEM-12 (NY) 40 6 24 29 100 199
TEM-16 80 76 65 100 100 421
TEM-17 0 29 6 43 0 78
TEM-24 100 82 82 86 100 450
TEM-26 (Ed) 60 65 47 43 100 315
TEM-26 (NY) 100 65 71 100 100 436
TEM-28 40 76 71 100 100 387
TEM-101 40 65 65 86 100 356
Mean values
for SHVs
48 71 65 80 80 344
Mean values
for TEMs
52 57 54 77 82 422
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NCCLS screening method, the Jarlier test per-
formed best with cefpodoxime, but also performed
well with cefoperazone, cefamandole and cefpir-
ome.
The disk-on-disk test can also be relatively easily
incorporated into routine disk susceptibility test-
ing, but requires some additional modifications.
As well as testing an appropriate cephalosporin
antibiotic on its own, it also needs to be tested in
combination with an appropriate b-lactamase inhi-
bitor. This test also requires that the plates be
incubated upside down relative to convention,
so that the upper disk does not fall off. After
incubation, a comparison between the zone sizes
of the cephalosporin with and without b-lactamase
inhibitor needs to be made, which will slightly
prolong the time taken to read the results. Since
this study was carried out, a commercial test based
on the same principle has been released. Oxoid
manufactures cefpodoxime (10-mg) disks and cef-
podoxime plus clavulanate (10- and 1-mg) disks. In
a recent study, 180 ESBL-producing klebsiellae
had enlarged cefpodoxime zones in the presence
of clavulanate of 5 mm [15]. Alternatively, the
NCCLS suggests that 10 mL of clavulanic acid at a
concentration of 1000 mg/L could be added to
ceftazidime or cefotaxime disks. Although this
works, disks have to be used immediately after
preparation and cannot be stored.
The modified three-dimensional test is probably
the least user-friendly of all those tested in this
study. It requires a considerable amount of time to
set up and extra resources in addition to those
used for routine susceptibility testing. Although
this was the case, the authors found the modified
three-dimensional test easier to carry out than the
original three-dimensional test [16]. Neither three-
dimensional test is recommended as a routine
screening test.
Originally, the makers of the ESBL E test strips
manufactured only ceftazidime/ceftazidime–cla-
vulanic acid strips. Consequently, many labora-
tories and research studies, including the current
study, use only these strips. Subsequently, the
manufacturers have started producing cefotax-
ime/cefotaxime–clavulanic acid, and now recom-
mend that both strips be used to test all relevant
isolates. The E test manufacturers have, over time,
made various recommendations concerning
which isolates should be tested. In the past, they
have recommended that all causative organisms of
Gram-negative nosocomial infections be tested
using their method, as well as all isolates exhibit-
ing reduced susceptibility to cefotaxime or cef-
triaxone, and in all cases of therapeutic failure
of Gram-negative infections, despite reported sus-
ceptibility to third-generation cephalosporins.
More recently, they have suggested that both cef-
tazidime/clavulanic acid and cefotaxime/cefotax-
ime–clavulanic acid strips should be used for
testing in cases of the suspected presence of ESBLs
in strains with phenotypic susceptibility patterns
where MIC values of aztreonam, cefotaxime cef-
tazidime, ceftriaxone or cefpodoxime are 1 mg/
L. Currently, each strip costs in excess of £2. At
Aberdeen Royal Infirmary, approximately 1500
Gram-negative isolates are reported from hospital
specimens per month. This translates into unrea-
listic and excessive costs to carry out routine E test
screening. In addition to the cost of the E test strips,
the method requires additional media costs and
operator time in setting up the test. Irrespective of
the costs involved, it is the opinion of the authors,
and of others [1], that the results of the ESBL E test
are not always easy to read. Very few of the test
isolates in this study gave clean zones of inhibition;
several of them showed the ‘phantom’ effect,
which could easily have been misread, and many
of them showed the effect as illustrated in Figure
5a, where extrapolation of the zone of inhibition at
the higher concentrations had to be carried out
before an MIC value could be established. In cases
where a phantom effect is observed, it is recom-
mended that even if the MIC ratios fall below the
designated threshold of 8, an isolate should be
considered as ESBL positive. Thus, the manufac-
turers over-rule the precise measurement of MICs,
on which their product is based, and rely on the
synergistic interactions between the relevant anti-
biotics, which form the basis of the Jarlier test. The
sensitivity of the ESBL E test has been reported to
be highly variable (52–100%). Nu¨esch-Inderbinen
et al. [17] found that the ESBL E test was only 52%
sensitive when compared with a PCR-based
method. Similar to our 77% sensitivity, Puyhardy
et al. [18] found that the test was 75% sensitive.
Vercauteren et al. [5] found the E test to be 81%
sensitive, and Cormican et al. [19] reported 100%
sensitivity.
The various methods did not differ greatly in
their abilities to detect either SHV or TEM ESBL
producers with the range of test antibiotics
(Table 2). The TEM ESBL producers, however,
were best detected by the modified three-dimen-
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sional and E test methods. In general, the selected
methods performed notably poorly in detecting
producers of TEM-7 and TEM-17. It is also notable
that the two isolates that produced TEM-10 and
the two that produced TEM-12 performed slightly
differently in this study. None of the methods
detected all of the TEM-derived ESBL producers
with any of the antibiotics. In contrast, all of the
SHV ESBL producers (but not the SHV-1 produ-
cer) were detected by the Jarlier method with the
antibiotics ceftazidime, cefoperazone, ceftriaxone,
cefotaxime, cefuroxime, cefamandole, ceftizoxime,
aztreonam and cefpirome; by the disk-on-disk
method with cefotaxime, ceftazidime, ceftizoxime,
cefpirome and cefepime; and by the modified
three-dimensional test with cefamandole. Thus,
it is easier to detect SHV ESBL producers than
TEM ESBL producers with the methods tested in
this study.
It should be borne in mind that the results of this
study are based on transconjugant isolates and on
examples of TEM- and SHV-related ESBL produ-
cers. A similar study carried out on clinical iso-
lates, the less ubiquitous ESBL enzymes and
organisms with multiple mechanisms of resis-
tance, would be useful in the future. This study
is useful, however, for evaluating and comparing
some of the more commonly used ESBL screening
tests against a wide range of antibiotics. None of
the antibiotics tested showed 100% sensitivity by
any of the methods, but several did come close. In
particular, cefoperazone, cefamandole, cefpodox-
ime and cefpirome showed good sensitivity across
the methods tested. Of those tested, the Jarlier test
and the disk-on-disk tests showed the best results.
In terms of practicality, we would recommend use
of either the Jarlier test or the commercial cepha-
losporin disks containing clavulanic acid to screen
for ESBL producers.
A C K N O W L E D G M E N T S
This work was presented, in part, at the 38th
Interscience Conference on Antimicrobial Agents
and Chemotherapy, 24–27 September 1998, San
Diego, California.
We are grateful to the following for supplying
control isolates: Professor S. G. B. Amyes, Depart-
ment of Medical Microbiology, The University of
Edinburgh; Dr Patricia Bradford, Wyeth-Ayerst
Research, Lederle Laboratories, New York; and
Dr D. Livermore, PHLS, London.
This work was funded by the Scottish Office
Home & Health Department, Grant No. RC278.
We are grateful to Mrs Anne Thomson for her
technical assistance.
R E F E R E N C E S
1. Bradford P. Extended spectrum b-lactamases in the
21st century: characterisation, epidemiology and
detection of this important resistance threat. Clin
Microbiol Rev 2001; 14: 933–51.
2. D’Agata E, Venkataraman L, DeGirolami P, Weigel
L, Samore M, Tenovar F. The molecular and clinical
epidemiology of Enterobacteriaceae producing ex-
tended spectrum b-lactamase in a tertiary care
hospital. J Infect 1998; 36: 279–85.
3. National Committee for Clinical Laboratory Stan-
dards. Performance standards for antimicrobial disk
susceptibility testing, 7th edn. NCCLS Document M2-
A7. Wayne, Pa: NCCLS, 2000.
4. Jarlier V, Nicolas M-H, Fournier G, Philippon A.
Extended broad-spectrum b-lactamases conferring
transferable resistance to newer b-lactam agents
in Enterobacteriaceae: hospital prevalence and
susceptibility patterns. Rev Infect Dis 1988; 10:
867–78.
5. Vercauteren E, Descheemaeker P, Ieven M, Sanders
CC, Goossens H. Comparison of screening methods
for detection of extended spectrum b-lactamases
and their prevalence among blood isolates of
Escherichia coli and Klebsiella spp. in a Belgium
teaching hospital. J Clin Microbiol 1997; 35: 2191–7.
6. Ericsson HM, Sherris JC. Antibiotic sensitivity
testing. Report of an international collaborative
study. Acta Pathol Microbiol Scand B Suppl 1971; 217.
7. MacKenzie FM, Gould IM. Extended spectrum b-
lactamases—commentary. J Infect 1998; 36: 255–8.
8. Emery CL, Weymouth LA. Detection and clinical
significance of extended spectrum b-lactamases in a
tertiary care medical centre. J Clin Microbiol 1997;
35: 2061–7.
9. Sanders CC, Barry AL, Washington JA et al.
Detection of extended-spectrum-b-lactamase-pro-
ducing members of the family Enterobactericeae
with the Vitek ESBL test. J Clin Microbiol 1996; 34:
2997–3001.
10. Moland ES, Sanders CC, Thomson KS. Can results
obtained with commercially available microscan
microdilution panels serve as an indicator of b-
lactamase production among Escherichia coli and
Klebsiella isolates with hidden resistance to ex-
panded spectrum cephalosporins and aztreonam.
J Clin Microbiol 1998; 36: 2575–9.
11. Bird J, Browning R, Hobson RP, MacKenzie FM,
Brand J, Gould IM. Multiply-resistant Klebsiella
pneumoniae: failure to spread in community based
elderly care facilities. J Hosp Infect 1998; 40: 243–7.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 715–724
MacKenzie et al TEM and SHV ESBL detection 723
12. Hobson RP, MacKenzie FM, Gould IM. An out-
break of multiply-resistant Klebsiella pneumoniae in
the Grampian region of Scotland. J Hosp Infect 1996;
33: 249–62.
13. Weller TMA, MacKenzie FM, Forbes KJ. Molecular
epidemiology of a large outbreak of multiply-
resistant Klebsiella pneumoniae. J Med Microbiol
1997; 46: 921–6.
14. Sirot J. Detection of extended-spectrum plasmid-
mediated b-lactamases by disk diffusion. Clin
Microbiol Infect 1996; 2(suppl 1): S35–9.
15. Carter MW, Oakton KJ, Warner M, Livermore DM.
Detection of extended spectrum beta lactamases in
klebsiellae with the Oxoid combination disk meth-
od. J Clin Microbiol 2000; 38: 4228–32.
16. Thomson KS, Sanders CC. Detection of extended-
spectrum b-lactamases in members of the family
Enterobacteriaceae: comparison of the double-disk
and three dimensional tests. Antimicrob Agents
Chemother 1992; 36: 1877–82.
17. Nu¨esch-Inderbinen MT, Ha¨chler H, Kayser FH. De-
tection of genes coding for extended spectrum SHV
beta lactamases in clinical isolates by a molecular
genetic method and comparison with the E test. Eur
J Clin Microbiol Infect Dis 1996; 15: 398–402.
18. Puyhardy JM, Chapalain JC, Cavallo JD, Plotton N,
Bietrix P. Evaluation of the E-test ESBL for detection
of extended spectrum beta lactamases in Antiinfec-
tive Drugs and Chemo therapy]. In: 6th BICON
Abstracts, Vol. 14. Abstract 1996: 169; 71.
19. Cormican MG, Marshall SA, Jones RN. Detection of
extended-spectrum b-lactamase (ESBL)-producing
strains by the E-test ESBL screen. J Clin Microbiol
1996; 34: 1880–4.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 715–724
724 Clinical Microbiology and Infection, Volume 8 Number 11, November 2002
